Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Heigener, David F.
42  Ergebnisse:
Personensuche X
?
1

Immune Checkpoint Inhibition in Non-metastatic Non-small Ce..:

Heigener, David F. ; Reck, Martin
Drugs.  79 (2019)  18 - p. 1937-1945 , 2019
Link: https://doi.org/10.1007/..
 
?
2

Behandlung des nichtkleinzelligen Lungenkarzinoms: Was blei..:

Heigener, David F. ; Schiller, Johanna ; Reck, Martin
Der Onkologe.  24 (2018)  10 - p. 831-842 , 2018
Link: https://doi.org/10.1007/..
 
?
3

Second-Line Treatment Selection in Patients With Non–Small-..:

Girard, Nicolas ; Corral, Jesus ; Cortinovis, Diego.
Clinical Lung Cancer.  18 (2017)  2 - p. e89-e97 , 2017
Link: https://doi.org/10.1016/..
 
?
4

Efficacy and Safety of Nintedanib Plus Docetaxel in Patient..:

Gottfried, Maya ; Bennouna, Jaafar ; Bondarenko, Igor...
Targeted Oncology.  12 (2017)  4 - p. 475-485 , 2017
Link: https://doi.org/10.1007/..
 
?
5

Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon E..:

Heigener, David F. ; Schumann, Christian ; Sebastian, Martin...
The Oncologist.  20 (2015)  10 - p. 1167-1174 , 2015
Link: https://doi.org/10.1634/..
 
?
6

Weekly and every 2 weeks cetuximab maintenance therapy afte..:

Heigener, David F. ; Pereira, José Rodrigues ; Felip, Enriqueta...
Targeted Oncology.  10 (2014)  2 - p. 255-265 , 2014
Link: https://doi.org/10.1007/..
 
?
7

Prospective, multicenter, randomized, independent-group, op..:

Heigener, David F. ; von Pawel, Joachim ; Eschbach, Corinna...
Lung Cancer.  80 (2013)  3 - p. 319-325 , 2013
Link: https://doi.org/10.1016/..
 
?
8

The gefitinib long-term responder (LTR)—A cancer stem-like ..:

Gottschling, Sandra ; Herpel, Esther ; Eberhardt, Wilfried E.E....
Lung Cancer.  77 (2012)  1 - p. 183-191 , 2012
Link: https://doi.org/10.1016/..
 
?
9

Response to Letter to the Editor:

Bischoff, Helge G. ; Heigener, David F. ; Walzer, Stefan.
Lung Cancer.  71 (2011)  2 - p. 245 , 2011
Link: https://doi.org/10.1016/..
 
?
10

Second-line erlotinib in patients with advanced non-small-c..:

Heigener, David F. ; Wu, Yi-Long ; van Zandwijk, Nico...
Lung Cancer.  74 (2011)  2 - p. 274-279 , 2011
Link: https://doi.org/10.1016/..
 
?
11

Mutations in the epidermal growth factor receptor gene in n..:

Heigener, David F. ; Reck, Martin
Advances in Therapy.  28 (2010)  2 - p. 126-133 , 2010
Link: https://doi.org/10.1007/..
 
?
12

Costs of bevacizumab and pemetrexed for advanced non-squamo..:

Bischoff, Helge G. ; Heigener, David F. ; Walzer, Stefan.
Lung Cancer.  69 (2010)  - p. S18-S23 , 2010
Link: https://doi.org/10.1016/..
 
?
13

Effectiveness of bevacizumab- and pemetrexed-cisplatin trea..:

Nuijten, Mark ; Heigener, David F. ; Bischoff, Helge G....
Lung Cancer.  69 (2010)  - p. S4-S10 , 2010
Link: https://doi.org/10.1016/..
 
?
14

Corrigendum to "Effectiveness of bevacizumab- and pemetrexe..:

Nuijten, Mark ; Heigener, David F. ; Bischoff, Helge G....
Lung Cancer.  69 (2010)  - p. S31 , 2010
Link: https://doi.org/10.1016/..
 
?
15

Societal cost savings through bevacizumab-based treatment i..:

Stanisic, Sanja ; Bischoff, Helge G. ; Heigener, David F....
Lung Cancer.  69 (2010)  - p. S24-S30 , 2010
Link: https://doi.org/10.1016/..
 
1-15